Ngomhlaka-29 Januwari 2025, ithimba locwaningo laseShayina lashicilela isihloko esithi “I-Neoadjuvant pyrotinib kanye ne-trastuzumab kumdlavuza webele we-HER2 omuhle ngaphandle kokusabela kwasekuqaleni (i-NeoPaTHer): ukusebenza kahle, ukuphepha, kanye nokuhlaziywa kwe-biomarker kocwaningo oluhleliwe, olunezikhungo eziningi, oluhambisana nokuphendula” kumagazini i-“Signal Transduction and Targeted Therapy”.
Umdlavuza webele we-human epidermal growth factor receptor 2 (HER2), obangela cishe u-15% kuya ku-25% wawo wonke umdlavuza webele, ubhekwa njengohlobo oluhlukile nolunolaka. Ubonakala ngokuvela ngokweqile kwe-HER2, i-transmembrane receptor tyrosine kinase ekhuthaza ukwanda kwamaseli omdlavuza nokusinda. Iziguli ezinomdlavuza webele we-HER2-positive zibhekene nengozi enkulu kakhulu yokuphinda zibuye futhi zife uma kuqhathaniswa nalezo ezinezinhlobo zomdlavuza webele, okwenza kube yisifo esinzima kakhulu ukwelapha. Kodwa-ke, isimo sokwelashwa komdlavuza webele we-HER2-positive siye sashintsha kakhulu eminyakeni engamashumi amabili edlule, ikakhulukazi ngenxa yokwethulwa kwezindlela zokwelapha eziqondiswe ku-HER2. Ikakhulukazi, ukufika kwe-trastuzumab kushintshe kakhulu indlela yomdlavuza webele we-HER2-positive kusuka esifweni esibulalayo kakhulu kuya kwesifo esinomphumela olawulekayo futhi ongemubi kangako.
Phakathi kuka-Okthoba 2020 noMashi 2022, iziguli ezingu-129 ezivela ezibhedlela ezinhlanu zabhaliswa kulolu cwaningo. Kulezi ziguli ezingu-129 ezibhalisiwe, ezingu-62 (48.1%) zahlonzwa njengeziphendula i-MRI (iqembu A), ezingaphenduli ezingu-26 zaqhubeka neminye imijikelezo emine ye-TCbH (iqembu B), kanti ezingaphendulanga ezingu-41 zathola i-pyrotinib eyengeziwe (iqembu C). Izinga le-tpCR lalingu-30.6% (95% CI: 20.6–43.0%) eqenjini A, 15.4% (95% CI: 6.2–33.5%) eqenjini B, kanye no-29.3% (95% CI: 17.6–44.5%) eqenjini C. Ukuhlaziywa kokuhlehla kwe-logistic okuguquguqukayo kubonise amathuba afanayo okufeza i-tpCR phakathi kwama-cohort A no-C (isilinganiso sezinkinga = 1.04, 95% CI: 0.40–2.70). Azikho izehlakalo ezintsha ezimbi ezibonwe ngokufakwa kwe-pyrotinib. Iziguli ezine-co-mutations ye-TP53 ne-PIK3CA zibonise amazinga aphansi okusabela okungaphelele kokuqala uma kuqhathaniswa nalezo ezingenayo noma ezine-gene mutation eyodwa (36.0% vs. 60.0%, P = 0.08). Lokhu okutholakele kusikisela ukuthi ukwengeza i-pyrotinib kungasiza iziguli ezingaphenduli ku-neoadjuvant trastuzumab kanye ne-chemotherapy. Uphenyo olwengeziwe luyadingeka ukuze kutholakale ama-biomarker abikezela izinzuzo zeziguli ngokufakwa kwe-pyrotinib.
Njengamanje, kusenezivivinyo eziningi zemitholampilo zobuchwepheshe obusha bokulwa nomdlavuza eShayina ezifuna iziguli. Ukubonisana ngemithi emisha kanye nobuchwepheshe, ungaxhumana noMnyango Wezizwe Ngezizwe Wesibhedlela iBeijing South Region Oncology.
Inombolo yocingo: 4008803716
Email：myimmnet@163.com
Izinkomba
https://www.nature.com/articles/s41392-025-02138-6
Isikhathi sokuthunyelwe: Feb-08-2025